LIST OF TABLES

Table 4.1. Some enzymes as drug targets. 44
Table 4.2. Some currently marketed drugs that target GPCRs. 45
Table 8.1. The active domains of Sp-AIr model with their sequence and E-value. 101
Table 8.2. Lipinski's Rule properties of L-Alanine (Substrate), D-cyclose-rine (Inhibitor) and Designed lead molecules (DLM 1 to DLM 24). 116
Table 8.3. Docked energy and RMSD of L-Alanine (Substrate), D-cyclose-rine (Inhibitor) and Designed lead molecules (DLM 1 to DLM 24). 117
Table 9.1. The active domains of Sp-Ddl model with their sequence and E-value. 137
Table 9.2. Lipinski's Rule properties of D-Alanine (Substrate), D-cyclose-rine and 3-chloro-2,2,-dimethyl-N-(4- (trifluoromethyl) phenyl) propanamide (Inhibitors) and Designed lead molecules (DLM 1 to DLM 24). 152
Table 9.3. Docked energy and RMSD of D-Alanine (Substrate), D-cyclose-rine and 3-chloro-2,2,-dimethyl-N-(4- (trifluoromethyl) phenyl) propanamide (Inhibitors) and Designed lead molecules (DLM 1 to DLM 24). 153
Table 10.1. The active domains of Sp-DltA model with their sequence and E-value. 175
Table 10.2. Lipinski's Rule properties of Lipinski's Rule properties of D-Alanine (Substrate), D-alanine adenylate (Ligand), 5'-O-[N-(D-Alanyl)-sulfamoyl]-adenosin and Ascamysin (Inhibitors) and designed lead molecules (DLM1 to DLM24). 190
Table 10.3. Docked energy and cluster RMSD of D-Alanine (Substrate), D-alanine adenylate (Ligand), 5'-O-[N-(D-Alanyl)-sulfamoyl]-adenosin and Ascamysin (Inhibitors) and designed lead molecules (DLM 1 to DLM 24). 193